Key result
The four-component polypill reduced systolic blood pressure by 9.9 mmHg and LDL-cholesterol by 0.8 mmol/L compared to placebo over 12 weeks, though it caused side effects in about 1 in 6 people.
Why the study?
Does a four-component polypill (aspirin, lisinopril, hydrochlorothiazide, simvastatin) reduce systolic blood pressure and LDL-cholesterol in individuals with an estimated 5-year cardiovascular disease risk over 7.5%?
RCT (n=378)
Double-blind
Computer-based minimization algorithm
Yes
Does a four-component polypill (aspirin, lisinopril, hydrochlorothiazide, simvastatin) reduce systolic blood pressure and LDL-cholesterol in individuals with an estimated 5-year cardiovascular disease risk over 7.5%?
A four-component polypill achieved sizeable reductions in systolic blood pressure and LDL-cholesterol in individuals with raised cardiovascular risk, though it caused side effects in about 1 in 6 people.
Answers are grounded in this paper and cite their sources.
Supports polypill initiation in moderate-risk patients; extends RCT evidence to those without component-specific indications.
BACKGROUND: There has been widespread interest in the potential of combination cardiovascular medications containing aspirin and agents to lower blood pressure and cholesterol ('polypills') to reduce cardiovascular disease. However, no reliable placebo-controlled data are available on both efficacy and tolerability. METHODS: We conducted a randomised, double-blind placebo-controlled trial of a polypill (containing aspirin 75 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg and simvastatin 20 mg) in 378 individuals without an indication for any component of the polypill, but who had an estimated 5-year cardiovascular disease risk over 7.5%. The primary outcomes were systolic blood pressure (SBP), LDL-cholesterol and tolerability (proportion discontinued randomised therapy) at 12 weeks follow-up. FINDINGS: At baseline, mean BP was 134/81 mmHg and mean LDL-cholesterol was 3.7 mmol/L. Over 12 weeks, polypill treatment reduced SBP by 9.9 (95% CI: 7.7 to 12.1) mmHg and LDL-cholesterol by 0.8 (95% CI 0.6 to 0.9) mmol/L. The discontinuation rates in the polypill group compared to placebo were 23% vs 18% (RR 1.33, 95% CI 0.89 to 2.00, p = 0.2). There was an excess of side effects known to the component medicines (58% vs 42%, p = 0.001), which was mostly apparent within a few weeks, and usually did not warrant cessation of trial treatment. CONCLUSIONS: This polypill achieved sizeable reductions in SBP and LDL-cholesterol but caused side effects in about 1 in 6 people. The halving in predicted cardiovascular risk is moderately lower than previous estimates and the side effect rate is moderately higher. Nonetheless, substantial net benefits would be expected among patients at high risk. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12607000099426.
No takes yet. Share an insight, caveat, or question.
A 2011 study conducted an RCT in Raised cardiovascular risk (n=378). Polypill (aspirin, lisinopril, hydrochlorothiazide, simvastatin) vs. Placebo was evaluated on Change in systolic blood pressure (SBP) at 12 weeks (MD 9.9 mmHg reduction, 95% CI 7.7 to 12.1, p=<0.0001). The four-component polypill reduced systolic blood pressure by 9.9 mmHg and LDL-cholesterol by 0.8 mmol/L compared to placebo over 12 weeks, though it caused side effects in about 1 in 6 people.
Synapse has enriched 10 related papers. Consider them for comparative context: